Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Victoza and Saxenda use another GLP-1 agonist, liraglutide. Tirzepatide — Eli Lilly’s branded versions are sold as Mounjaro for blood sugar and Zepbound for weight loss — works on two hormones.